Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Pharmacoepidemiology and Drug Safety|March 7, 2024
Effect of statin treatment on the risk of cancer in patients with heart failure: A target trial emulation studyChengsheng Ju, Wallis C Y Lau, Pinkie Chambers, et al.
BMJ Neurology Open|January 9, 2026
Prospective assessment of serum neurofilament light chain in platinum-induced and taxane-induced peripheral neuropathyDuncan Smyth, Ryan Y S Keh, Stephen Keddie, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancerDavid A Moore, Sarah Benafif, Benjamin Poskitt, et al.
Cancer Medicine|August 23, 2023
Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic functionPinkie Chambers, Matthew Watson, John Bridgewater, et al.
Nature Reviews. Clinical Oncology|April 7, 2011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancerMartin D Forster, Konstantin J Dedes, Shahneen Sandhu, et al.
Cancer Research|December 17, 2005
BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumorsDavid D Gibbs, Davinder S Theti, Nadya Wood, et al.
The Oncologist|September 8, 2024
The impact of inter-cycle treatment delays on overall survival in patients with advanced-stage ovarian cancerLuke Steventon, Kenneth K C Man, Shibani Nicum, et al.
Cancer|January 9, 2014
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trialsChara Stavraka, David J Pinato, Samantha J Turnbull, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort studyLuke Steventon, Emma Kipps, Kenneth Kc Man, et al.
Plos One|January 11, 2014
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trialsDavid J Pinato, Chara Stavraka, Michael J Flynn, et al.
Pageof 6